PCM
CHTP

Prelude Capital Management’s CHELSEA THERAPEUTICS INT'L LTD CHTP Stock Holding History

Prelude Capital Management’s Portfolio CHTP Stock Details CHTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-8,367
Closed -$37K – 2324
2013
Q4 		$37K Hold
8,367
– – 0.01% 1165
2013
Q3 		$25K Sell
8,367
-12,633
-60% -$36.3K ﹤0.01% 1205
2013
Q2 		$48K Buy
+21,000
New +$42.5K 0.01% 835

Other funds holding CHTP

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GH
Green Holdings Hamilton, Bermuda $9.16M AUM 15.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's CHTP Position: Q1 2014 in Review

Prelude Capital Management sold out of CHELSEA THERAPEUTICS INT'L LTD (CHTP) in Q1 2014, closing a stake of 8,367 shares — an estimated $37K sold.

Prelude Capital Management first reported a position in CHTP in Q2 2013 and held it in 3 quarters. The position peaked at $48K in Q2 2013. 85 funds tracked by Wall St. Rank hold CHTP as of Q1 2014.

  • Prelude Capital Management reported no remaining CHELSEA THERAPEUTICS INT'L LTD position as of Q1 2014 after selling out during the quarter.
  • Prelude Capital Management sold 8,367 CHELSEA THERAPEUTICS INT'L LTD shares in Q1 2014, an estimated $37K.
  • Prelude Capital Management first reported a position in CHELSEA THERAPEUTICS INT'L LTD in Q2 2013 and held it in 3 quarters.
  • Prelude Capital Management's CHELSEA THERAPEUTICS INT'L LTD position peaked at $48K in Q2 2013.
  • 85 funds tracked by Wall St. Rank held CHELSEA THERAPEUTICS INT'L LTD as of Q1 2014.

Based on Prelude Capital Management's 13F filing for Q1 2014, filed 15 May 2014.